Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€28.35

€28.35

-1.570%
-0.45
-1.570%
€100.00
 
08.07.25 / Tradegate WKN: A1EWVY / Name: Formycon / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Formycon AG Stock

A loss of -1.570% shows a downward development for Formycon AG.
Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Formycon AG is rather balanced.
With a target price of 100 € there is potential for a 252.73% increase which would mean more than doubling the current price of 28.35 € for Formycon AG.
Our community identified positive and negative aspects for Formycon AG stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Formycon AG stock. On the other hand our users think that "Valuation (undervalued/overvalued)" could be a problem in the future.

Pros and Cons of Formycon AG in the next few years

Pros
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Formycon AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Formycon AG -1.570% 0.890% 4.037% -49.555% -46.000% -62.150% 14.777%
MagForce AG -20.000% -33.333% -69.231% 100.000% 700.000% -99.752% -99.871%
B.R.A.I.N. Biotechnology Research and Information Network AG 0.800% -1.571% -10.048% -14.932% -46.286% -75.835% -77.295%
Ardelyx Inc. 3.200% 15.519% 18.636% -24.087% -22.941% 454.895% -38.784%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon initial analysis of Formycon's financial statements, it's evident that this biotechnology and medical research company has seen substantial fluctuations in its financial position over the years. While it may have experienced a few challenges, there are also some notable strengths present in the company's financials. This report aims to provide an in-depth analysis, highlighting both the pros and cons to help potential investors make an informed decision based on Formycon's financial health.

Growing Total Assets: From 2019 to 2021, Formycon has experienced significant growth in its total assets, going from €53,555,323.89 to €66,333,000.00. This uptick is a positive sign, indicating that the company's financial position is improving, and there is potential value generated from its operations.

Reduced Liabilities: The total liabilities of Formycon have shown a decreasing trend, moving from €5,344,603.40 in 2019 to €4,269,670.00 in 2021. A decrease in liabilities is an encouraging sign, suggesting that the company is managing its debt levels effectively.

Comments

Buy Formycon AG
Show more

News

EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
EQS-News: Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
EQS-News: Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
EQS-News: Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond
EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond
EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond